India Globalization Capital (NYSE MKT: IGC), an innovator in developing cannabis-based combination therapies to treat pain and other conditions, is currently applying the revolutionary seizure-treating potential of CBD to another population: domestic pets, and the company is addressing the 5 percent of dogs and just over 2 percent of cats in the United States that experience seizures.
Cannabidiol (CBD) has been scientifically shown to be effective in the treatment of certain epilepsies, pain, inflammation and nausea, as well as providing relief from hangover, anxiety and stress.
NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
PI has put a “Buy” rating on the stock and set a one-year price target of $2.25, implying a return of well over 100 percent.
Before the opening bell, top-ranked independent research firm WallStreet Research™ (WSR) announced the release of a Corporate Profile Analyst Report covering ChineseInvestors.com, Inc. (OTCQB: CIIX).
In addition to its San Gabriel store, the company also owns and operates an online store based in the free trade zone of Shanghai, China.
ABcann is new to the public market, having launched its initial public offering on May 4. However, the company is one of the most experienced Canadian growers.
Also known as Lou Gehrig’s disease, ALS is a fatal illness that attacks the nerve cells that control voluntary muscles such as those in the face, arms, legs, and others.
It plans for a brick-and-mortar store in San Gabriel, California, as well as recently incorporating CBD Biotechnology, Inc., in British Columbia, Canada. It also has an online CBD store with hemp-based products located in the free trade zone of Shanghai, China, designed to serve the global Chinese-speaking population.
Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space.
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://nnw.fm/SVF1j), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed.
Growing marijuana in North America, for obvious reasons, has historically been an underground affair. Amid growing legalization in favor of recreational and medicinal use, growing cannabis on mass scale is rapidly becoming a necessity for companies in a burgeoning industry driven by incredible consumer demand.
With the North American cannabis market boasting an estimated worth of $7.2 billion in 2016, and new reports projecting CAGR of between 17 percent and 25 percent within the next few years, it’s certainly an exciting time to invest in the marijuana market.
The nutraceutical industry boasts a diversified playing field, and Canada-based Algae Dynamics Corp. (OTCQB: ADYNF) is taking a unique approach to this burgeoning market, focusing on the development of proprietary research and products that combine the health benefits of botanical oils derived from cannabis and algae.
ChineseInvestors.com (OTCQB: CIIX) is a leading financial information website for Chinese-speaking investors in the United States and China.
